[CAS NO. 2986319-18-8] S19-1035
PRODUCTS SPECIFICATIONS [2986319-18-8]
DESCRIPTION [2986319-18-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 356.80 |
| Molecular Formula | C19H17ClN2O3 |
| SMILES | CC1=NOC(C)=C1COC2=CC=CC=C2C(NC3=CC=CC=C3Cl)=O |
Summary
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC 50 value of 3.04 nM. S19-1035 can be used for the research of tumor [1] .
IC50 & Target
IC50: 3.04 nM (AKR1C3) [1]
In Vitro
S19-1035 exhibits inhibitory activity for AKR1C3 with an IC
50
value of 3.04 nM
[1]
.
S19-1035 (0-100 μM; 72 h or 96 h) has less cytotoxic and had limited antitumor effects when used alone
[1]
.
S19-1035 (10 μM; 8 days) significantly reversed the doxorubicin (DOX) resistance in a resistant breast cancer cell line in co-administration
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
| Cell Line: | MDA-MB-231, MCF-7 and MCF-7/DOX cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 72 h or 96 h |
| Result: | Had weak antiproliferative effects in all three breast cancer cell lines. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.